Introduction 1
Cancer cells are known to be addicted to high levels of transcription as the 2 enhanced expression of a plethora of molecules is required for the generation and 3 the maintenance of a transformed phenotype (1, 2) . This information suggests that 4 the different factors that participate in general transcriptional activation by RNA 5 polymerase II (RNAPII) could be targets for treating cancer. Since RNAPII is not 6 able to recognize the promoter and initiate transcription in a regulated way by itself, 7 it requires the assembly of what is known as the pre-initiation complex (PIC) at 8 promoters. Generally, the PIC includes the TFIID complex, RNAPII, TFIIB, TFIIA, 9 TFIIF, TFIIE, and TFIIH (3). In metazoans, during transcriptional activation, RNAPII 10 synthesizes a transcript with a length of 20-120 nucleotides and then it pauses 11 (4,5). The release of paused RNAPII is conducted by the positive-elongation factor 12 pTEFb (6,7). 13
A component of the PIC and an interesting target to affect transcription-14 and therefore, cancer-is TFIIH (8, 9) . TFIIH is a complex of 10 subunits composed 15 of the CAK subcomplex containing CDK7, CYCH, and MAT1, which also 16 participates in cell cycle control, and the core subcomplex that is part of the 17 mechanism of nucleotide excision repair (NER) (10). The core subcomplex is 18 composed of P8, P34, P44, P52, P60, XPB and XPD subunits (the last two are 19 DNA helicases/ATPases) (11). Together, the CAK and the core form the 10-20 subunit TFIIH complex, which participates in transcription (11, 12) . The role of 21 TFIIH in RNAPII transcription involves phosphorylation of Ser 5 in the RNAPII CTD 22 (p Ser5 CTD RNAPII) by CDK7, which is important for transcription initiation, 23 recruitment of the CAP enzyme, other modifications and mRNA processing (12-24 14) . In contrast, XPB functions as an ATP-dependent translocase that rotates DNA 25 to open it around the transcription initiation site, facilitating the synthesis of RNA by 26 RNAPII (15, 16) . Thus, compounds that affect the TFIIH functions have been found 27 or developed as strong candidates to combat cancer. For instance, THZ1 and 28 related compounds inhibit the kinase activity of CDK7 by binding a protein region 29 outside of its catalytic domain (Cys312) (17) and is very effective in killing different 30 types of cancer cells (18) . On the other hand, triptolide (TPL), inhibits the ATPase 31 bath sonicator). 5% of the lysate was reserved as Input. Lysate was incubated with 1 5 mg of the antibody (8WG16) or irrelevant rabbit IgG (Invitrogen). Library 2 construction and Illumina sequencing were performed using Illumina HiSeq SE50 3 platform at BGI. 4
Briefly, data filtering included removing adaptor sequences, contamination and low-5 quality reads from raw reads by BGI programs, like SOAPnuke filter., Clean data 6 were mapped to the reference genome (hg19) by SOAPaligner/SOAP2 (35). 7 MACS2 v1.4.2 (36) was used to call peaks and generate Bedgraph files that show 8 fold change enrichment over input. Bedgraph files were then converted into BigWig 9 files and uploaded to UCSC Genome Browser for visualization. 10 HOMER (Next-Generation Sequencing Analysis -annotatePeaks.pl) (37) was used 11 to annotate the peaks to the genome. Difference in RNAPII enrichment between 12 TPL-treated and control cells we performed a differential binding analysis using 13 HOMER (getDiffExpression.pl). Differential expression data was filtered using log 14 between RNA-Seq and ChIP-Seq analyses we considerate only the RNAPII peaks 19 located a ± 1 kb window spanning the Transcription Start Site (TSS). Differential 20 expression data were filtered using log FC ≥ 1 for ChIP-Seq and log FC ≥ 1.2 for 21 RNA-Seq. Graph was made GraphPad Prism ( Fig 4C) 22
Accession number for raw and processed ChIP-Seq and RNA-Seq data reported in 23 this paper is GEO: GSE135256. 24 25 Molecular dynamics. The cryo-electron microscopy structure of Homo sapiens 26 TFIIH (PDB ID: 6NMI(38)) was retrieved from the Protein Data Bank ( Fig 2F) . The 27 insolated XPB-P52-P8 submodule (17) as employed to perform the covalent 28 docking of the optimized TPL structure into Cys342 residue of the XPB component 29 employing the AutoDock v4.2 (39). The Apo and two holo (TPL-bound) forms of 30 XPB-P52-P8 submodule were submitted to 100 ns all-atom molecular dynamics 31 (MD) simulations using the AMBER99SB-ILDN force field (40) implemented in the 1 GROMACS 5. 1 and Supplementary Table S2 . To study the effects of TPL and THZ1 on cancer cells and their progenitors, we 8 used the MCF10A-ErSrc cell line as an oncogenesis model (24). After 36-72 h of 9 incubation with tamoxifen, the MCF10A-ErSrc line is transformed, it is highly 10 proliferative, has lost adherence, forms mammospheres, generates tumours and 11 metastasis in immunocompromised mice. In this study, cells with these 12 characteristics are referred to as TransFormed (TF) and their progenitors as Non-13
TransFormed (NTF). Phosphorylated STAT3 (pSTAT3) was used as a 14 transformation control in this line (24,42) 15
To analyse whether TF cells are more sensitive than NTF cells when TFIIH 16
is affected, we evaluate by flow cytometry viability of NTF and TF cells which were 17 incubated with TPL, THZ1 or both chemicals at different concentrations and for 18 different times (Fig. 1A) . The viability of both NTF and TF cells was highly affected 19
by the presence of TPL, with TF cells being more sensitive (Fig. 1A ). Following 20 incubation with 100 nM TPL for 72 h, approximately 90% of TF cells died ( Fig. 1A) . 21
However, at the same concentration and incubation time, more than 50% of NTF 22 cells were still viable. In contrast, at a concentration of 250 nM THZ1 for 72 h, 23 approximately 64% of TF cells died, and only 36% of NTF cells died ( Fig. 1A) . 24
Interestingly, simultaneous incubation of NTF and TF cells with both chemicals had 25
an additive effect on cell viability ( Fig. 1A) , as practically all TF cells died after 48 h 26 when incubated with TPL (100 nM) and THZ1 (250 nM) ( Fig. 1A ). However, under 27 those conditions and even after 72 h, approximately 40% of NTF cells remained 28 viable ( Fig. 1A) . Thus, the combination of TPL and THZ1 is better than either drug 29 alone and it preferentially targets TF cells for cell death. In all cases, cells died via 30 apoptosis ( Supplementary Fig. S1 ). 31 Next, we evaluated by flow cytometry assays the effect of TPL, THZ1 and 1 the combination of both at different concentrations and times on proliferation and 2 cell cycle progression in NTF and TF cells ( Fig. 1B-C) . Figure 1B shows that after 3 72 h of incubation with 25 nM TPL, TF cells stopped after two cycles of 4 proliferation; and that NTF cells required 100nM TPL to stop proliferating ( Fig. 1B) . 5
Similarly, TF and NFT cells stopped proliferating, when incubated with 100 nM or 6 250 nM THZ1 for 72 h, respectively ( Fig. 1B) . Interestingly, when incubated with 7 both TFIIH inhibitors NTF and TF cells stopped proliferating with only 25 nM TPL 8 and 50 nM THZ1, confirming the additive effect of these drugs ( Fig. 1B) . 9
Furthermore, we found that in the presence of TPL and THZ1, cells were arrested 10 at the G 1 phase and that lower concentrations of TPL and THZ1 were needed for 11 TF cells (Fig. 1C ). Taken together, these results indicate that TF cells are more 12 sensitive to TPL and THZ1 than their NTF cells counterparts. TF cells stopped 13 proliferating and were arrested at G 1 at lower concentrations and shorter 14 incubation times when incubated with either drug. Importantly, simultaneous 15 treatment with TPL and THZ1 had a significantly more severe effect on TF cells 16 than on NTF cells and than either drug used independently, underscoring the 17 potential of simultaneously inhibiting different TFIIH activities with TPL and THZ to 18 develop alternative therapies for cancer treatment. 
22
Based in our previous analysis of TFIIH mutants in Drosophila (43), we 23 sought to explore the effect of TPL on the XPB levels in NTF and TF cells. Cells 24 were incubated with 125 nM TPL for different times. Since the disruption of 25 transcription by RNAPII causes degradation of this enzyme, we also evaluated 26 levels of RNAPII as well as of other TFIIH subunits. As expected, levels of 27 RNAPII-and therefore, p ser5 CTD RNAPII-decreased as a result of incubating the 28 cells with TPL ( Fig. 2A) . A clear reduction in XPB protein was also observed, which 29 was greater in TF cells ( Fig. 2A ). Furthermore, levels of the P52 and P8 subunits 30 were also diminished in response to TPL exposure ( Fig. 2A ). However, levels of 31 other subunits of TFIIH, such as XPD, CDK7, CYCH, and MAT1, were not affected 1 ( Fig. 2A ). As expected, incubation with THZ1 for different times reduced the levels 2 of p ser5 CTD RNAPII, but it did not affect the levels of this enzyme or the levels of 3 any TFIIH subunit, including the CAK subcomplex, consistent with previous reports 4 (44) ( Supplementary Fig 2A) . 5 XPB directly contacts the P52 and P8 subunits and this interaction 6 modulates the ATPase activity of XPB (43,45). Since our results suggested that the 7 binding of TPL to the ATPase domain of XPB destabilizes XPB as well as P52 and 8 P8, we investigated whether TPL causes a distortion of XPB that limits the 9 interaction of XPB with P52 and P8. To achieve this aim, we used the public 10 information recently reported for the structure of the human TFIIH core by cryo-11 electron microscopy (38). TPL inhibits XPB ATPase function through the formation 12 of a covalent bond between the C12 carbon (12,13-epoxide group) on the inhibitor 13 and the sulfur atom of the Cys342 residue of XPB (TPL C12 -Cys342) (46). The 14 isolated XPB-P52-P8 putative submodule was employed to perform molecular 15 dynamics (MD) simulations of the covalent docking of the optimized TPL structure 16
to the Cys342 residue of XPB ( Fig. 2B ). Our covalent docking study showed that 17 the TPL binding site (TBS) in XPB is located at the interface of the helicase 18 domains (HD1 and HD2), which are mainly constituted by DEVH box residues 19 ( Supplementary Fig. 3 ). During the MD simulations, the presence of TPL at the 20 HD1-HD2 interface altered the number of contacts between both domains, which 21 may lead the separation of the domains and that the dissociation could be due to 22 allosteric modulation guided by the loss of interactions between the XPB N-23 terminal domain (NTD) and P52 and between XPB HD2 and P52/P8. 24
To confirm the MD results we performed split-GFP-complementation assays 25 between XPB and P52 by using the tripartite split-GFP association system (27). 26
Stable HEK-293 cells expressing GFP1-9 were co-transfected with GFP10-P52 27 and XPB-GFP11 constructs an incubated with TPL at different low concentrations 28 for 28 h (Fig. 2C ). As a control, we used a GCN4 homodimeric interaction (GFP10-29 GCN4 and GCN4-GFP11) previous reported (27). The GFP fluorescence signal 30 was quantified only in living cells by flow cytometry. After the TPL treatment a clear 31 reduction in the fluorescence is observed in the P52-GFP-XPB-complementation 1 cells, but not in the control cells ( Fig. 2C ). These in vivo results are in agree with 2 structural modelling results that suggest that TPL interferes with the binging 3 between XPB and P52. Altogether, results of this section suggest that XPB, P52, 4 and P8 form a submodule in the core of TFIIH and that TPL besides to inhibit the 5 XPB-ATPase activity, also cause the XPB-P52-P8 destabilization without affecting 6 the rest of the TFIIH subunits. While analysing the transcriptome of TFIIH mutants in Drosophila, we previously 11 reported that not all genes responded equally and that the transcript levels of 12 numerous genes increase in TFIIH mutant tissues (47,48). Therefore, to explore 13 whether TPL also generates a differential effect on gene expression in TF and NTF 14 cells, we analysed the transcriptomes of these cells after incubation with 125 nM 15 TPL for 4 hours, a concentration found to reduce equally RNAPII levels by half in 16 NTF and TF cells, to affect mildly cell viability ( Fig. 3A-B) . 17
Approximately 18,500 different transcripts were identified in both TF and 18 Fig 4A) . Correlation analysis between NTF and TF cells 19 with and without TPL showed, as expected, that the treatment with TPL caused a 20 reduction in the transcript levels of some genes, but intriguingly, the levels of other 21 transcripts increased ( Fig. 3C ; Supplementary Fig 4B) . Induction of the 22 transformed phenotype of MCF10A-ErSrc cells reduced the expression of 6.84% 23 and increased the expression of 6.59% of the genes (Fig. 3D ). When we compared 24 the effect of TPL in NTF and TF cells, the RNA levels of approximately 68% of the 25 genes did not significantly change, probably because in the conditions used in this 26 experiment, the reduction in transcription initiation of many genes is not detected 27 by RNA-Seq ( Fig. 3D ). However, in both, NTF and TF cells, approximately 11% of 28 the gene transcript levels were increased, and approximately 19% were decreased 29 ( Fig. 3D ). Among the downregulated genes, 2135 transcripts were shared between 30 NTF and TF cells. Among the upregulated genes, 1681 transcripts were common 31 to NTF and TF cells, 62 were exclusive to NTF cells, and 36 were exclusive to TF 1 cells ( Fig. 3E ; Supplementary Table S3 ). The expression of 213 genes were 2 exclusive to either NTF or TF cells ( Fig. 3F ). Some genes as SOX9, RETL1 and 3 IGFBP3, were downregulated in NTF cells and upregulated in TF cells in response 4 to TPL. However, we also detected genes whose transcripts were upregulated in 5 NTF cells and downregulated in TF cells, such as FAM111B and F2R 6 ( Supplementary Table S3 ). Intriguingly, most of the recently identified factors 7 required to maintain the oncogenic state in TF cells (49), change its expression 8 back to NTF condition, suggesting a partial reversion of TF to NTF phenotype ( Fig.  9 3G). 10
NTF cells (Supplementary
To confirm the RNA-Seq results, a set of 14 randomly selected genes was 11 analysed by RT-PCR, and exhibited the same behaviour as shown by the RNA-12
Seq data ( Supplementary Fig 5A) . In addition, we explored whether a similar 13 response to TPL occurs in other breast cancer cell lines (MCF-7 and MDA-MB-14 231) ( Supplementary Fig 5A) . Twelve out of the fourteen genes had a similar 15 behaviour across all cells tested ( Supplementary Fig 5A) , indicating that breast 16 cancer cell lines have a similar gene expression response to TPL. 17
All together our data indicate that XPB inhibition by TPL differentially 18 modulates many genes in NTF and TF cells. Unexpectedly, the RNA-Seq results 19
indicate that even when TPL affects RNAPII transcription, some genes are 20 upregulated in response to this insult. This result suggests that there are genes for 21 which, transcription may continue or even increase under conditions in which the 22 levels of RNAPII are reduced as well as the XPB-P52-P8 submodule. The increase in the RNA levels of numerous genes in response to TPL can be a 27 result of different factors, including enhancement of transcription and/or an 28 increase in accumulation of some RNAs by reducing their degradation. Reports 29 using TPL to analyse pausing at promoters have been described (50,51). However, 30 the effect of TPL on RNA levels under conditions when the level of RNAPII is 31 reduced was not determined in any of these studies. Therefore, we sought to 1 analyse the genomic occupancy of RNAPII by chromatin immunoprecipitation 2 followed by next-generation sequencing (ChIP-Seq) in NTF and TF cells incubated 3 with or without TPL under similar conditions as those used in the RNA-Seq 4 experiments. 5
Overall, the metagenome analysis showed that occupancy of RNAPII on the 6 promoters was higher in TF cells than in NTF cells. As expected, we observed a 7 reduction in the occupancy of RNAPII in NTF and TF cells when treated with TPL, 8
with the main peak that corresponds to paused RNAPII in TPL-treated cells 9 displaced to the 5´ end of the transcription start site (TSS) (Fig. 4A ). This data 10
shows that most RNAPII accumulates in the initiation state (PIC) and is in 11 agreement with previous results on the effect of TPL on RNAPII occupancy on 12 gene promoters (50,51). Also consistent with the existence of highly stable paused 13 promoters (50), since promoters corresponding to paused RNAPII were still 14 detected ( Fig. 4A ). However, in our experiments, we identified stably paused 15 promoters in cells with a substantial reduction in the levels of RNAPII and the XPB-16
P52-P8 submodule of TFIIH. Additionally, some promoters exhibited an increase in 17 RNAPII occupancy in NTF (5.42%) and TF (3.9%) cells incubated with TPL ( Fig.  18 4B; Supplementary Table S4) , 19
Since the RNA-Seq results indicated that some transcripts were upregulated 20 by TPL, we assessed whether there was a correlation between the occupancy 21 level of RNAPII on the promoters with transcripts that were up-or downregulated in 22 response to TPL. As shown in Figure. 4C, in TPL-treated NTF and TF cells, 261 23 and 301 genes respectively, were found to have an increased association of 24 RNAPII to their promoters, and that correlated with a significant increase in their 25 corresponding RNA levels ( Supplementary Table S4 ). Of these genes, 157 were 26 shared between NTF and TF cells ( Fig. 4C ). Also, an increase of RNAPII in the 27 body of these genes is observed ( Fig. 4D ). 28
The correlation analyses indicated that there were different gene expression 29 pattern in response to TPL (Fig. 4C ). There were genes such as FOS, on which 30 paused RNAPII was cleared, but initiating RNAPII was enriched and whose 31 transcript levels were reduced by TPL in NTF and TF cells ( Fig. 4D ; 1 Supplementary Table S4 ). For other genes, such as SOX9, the mRNA levels 2 decreased in the presence of TPL in NTF cells, but in TF cells, TPL induced a 3 significant increase in the RNA levels as well as an increase in RNAPII promoter 4 occupancy of these same genes ( Fig. 4D ; Supplementary Table S4 ). The VEGFA 5 gene was overexpressed in TF cells, with high levels of RNAPII in the body of the 6 gene, but TPL repressed its expression, reducing the occupancy of RNAPII ( Fig.  7 4D). The most intriguing response to TPL occurred in genes that were upregulated, 8 such as LOC730101 and HEXIM1, in which RNAPII occupancy on the promoter 9 and along the body of the gene were increased (Fig. 4D) . Interestingly, the effect of 10 TPL on transcription induced potent overexpression of the gene that encodes for 11 the large subunit of RNAPII (POLR2A) ( Fig. 4D ). We confirmed that the increase in 12 levels of the mRNAs is due to an enhancement of transcription in response to TPL 13 by evaluating the novo transcription of the first intron pre-mRNA of POLR2A, CLU 14 and ID2 genes by qRT-PCR ( Fig. 4E ). 15
Next, we performed a gene ontology analysis focusing on cancer related 16 genes in which RNAPII occupancy on the TSS as well as its RNA levels was 17 increased ( Fig. 4F ; Supplementary Table S5 ). A large number of genes that 18 function as tumour and growth suppressors, such as PHACTR4 and ARID4A 19 (52,53), as well as genes that correspond to chemotherapy/radiotherapy response 20 genes, such as SNAI1 and SNX1 (54,55) , were overexpressed. However, a large 21 number of genes considered as oncogenes or that promote tumour growth and/or 22 metastasis, such as SKI, EGR4, SNAI1 and CEMIP2 (55-58), were also 23 overexpressed in response to TPL ( Fig 4F; Supplementary Table S4 ) 24
To confirm whether genes exhibiting an increase in RNAPII promoter 25 occupancy were also overexpressed in response to TPL and for further analysis, 26 we selected five genes with different cellular functions for qRT-PCR. The selected 27 genes were ID2, a transcription factor known to participate in epithelial-28 mesenchymal transition (59); CRY2, a circadian repressor involved in MYC 29 turnover (60); long noncoding RNA (lncRNA) LOC730101, which is induced by 30 hypoxia and has been related to metastasis (61); and HEXIM1, an inhibitor of 31 pTEFb, linked to chemotherapy resistance and that it has been shown that also is 1 overexpressed in response to JQ1 (62,63). In addition, we analysed EPAS1, also 2 known as HIF-2A, a transcription factor that responds to hypoxia, a hallmark of 3 cancer. EPAS1 is overexpressed in TF cells and its transcript levels were high and 4
maintained in cells incubated with TPL (59). For all genes, the increase in RNA 5 levels was confirmed ( Fig. 5A-E) . A kinetic analysis of the encoded products of 6 these genes by western blot confirmed that not only the accumulation of the RNA 7 increase, but also the corresponding protein in response to TPL (Fig. 5F) . 8
Furthermore, we verified the increase in the expression of these genes in response 9
to TPL in other breast cancer cell lines by RT-PCR. Interestingly, these genes were 10 also overexpressed in the MCF-7 and MDA-MB-231 breast cancer cell lines in 11 response to TPL, indicating that this response is not exclusive to the MCF10A-12
ErSrc line (Supplementarry Fig. 6 ). Collectively, our results indicate that both NTF 13 and TF cells respond to a TPL insult by inhibiting RNA transcription. Yet, despite 14 TPL directly affects transcription initiation, and significantly reduces the levels of 15 RNAPII as well as of the XPB-P52-P8 submodule components of TFIIH, the 16 transcriptional stress imposed to the cells results in activation of selected genes. 17
Among those, genes that suppress cancer growth are overexpressed, but 18 importantly, genes that promote carcinogenesis, chemotherapy resistance and 19 metastasis are also upregulated. 20
21

THZ1 drives a similar gene response as TPL in cancer cells
22
Next, we decided to explore whether incubation with THZ1 induces a similar gene 23 response as TPL. The first approach to answer this question was to determine, by 24 RT-PCR, the response of some of upregulated genes in response to TPL in NTF 25 and TF cells when incubated with THZ1. For this experiment, we used a 26 concentration of 300 nM THZ1 for 2 h (Fig. 6A ). Figure 6B shows that for ID2, 27 lncRNA LOC730101, HEXIM1 and EPAS1, there was a clear increase in the 28 mRNA levels in NTF cells incubated with THZ1 ( Fig. 6B ). In TF and NTF cells, the 29 mRNA levels of ID2 and the lncRNA increased and similar behaviour of EPAS1 as 30 that seen with TPL incubation was observed ( Fig. 6B) . In contrast, no clear 31 increase in the HEXIM1 transcript level was observed in TF cells, and in all cell 1 types, CRY2 level remained the same in THZ1-treated cells. These results suggest 2 that there are some similarities in the gene expression responses to TPL and THZ1 3 in NTF and TF cells, but that the responses are not identical. 4
To explore how similar the gene expression responses to TPL and THZ1 are, we 5 used public RNA-Seq data from an oesophageal cancer cell line treated with THZ1 6 (64). We found that 94 genes upregulated by TPL that correlated with an increase 7 in the occupancy of RNAPII in the oncogenesis model used here were also 8 upregulated by THZ1 in the oesophageal cancer cell line ( Fig 6C) . These results 9
suggest that in response to transcriptional stress by either TPL or THZ1, a similar 10 set of genes is overexpressed. The fact that some genes are overexpressed in response to TPL underscored the 15 possibility that some of them were targets for tumour cell killing. To explore the 16 likelihood that depleting the transcripts of genes overexpressed in response to TPL 17 potentiates the killing effect of TPL, we chose to evaluate the effect of silencing 18 ID2, CRY2, HEXIM1, LOC730101 and EPAS1 on cell viability and proliferation. 19
NTF and TF cells were transfected with pooled siRNAs against each of these 20 transcripts for 24, 48 or 72 hours, followed by incubation with 125 nM TPL for 4 h. 21
Consistent with data shown above, 125 nM TPL alone or in combination with the 22 scrambled siRNAs did not affect NTF and TF cells survival ( Fig. 7 , middle panels). TPL, but the effect of silencing this lncRNA, intensified the killing capacity of TPL in 31 both NTF and TF cells ( Fig. 7E, middle panel) . Surprisingly, reducing the levels of 1 EPAS1 (HIF-2A) RNA did not result in enhanced killing capacity of TPL ( Fig. 7D , 2 middle panel). Unlike NTF cells, the majority of surviving TF cells underwent at 3 least one round of proliferation less than NTF transformed cells following RNA 4 silencing of all genes (including EPAS1) and TPL treatment, or even two. (Fig. 7A -5 E, right panels), In summary, these results show that depletion of some genes 6 overexpressed in response to TPL sensitizes cells to TPL treatment; therefore, 7 these genes are possible targets to enhance the killing effect of TPL on cancer 8 cells. 9 10 Discussion 11
The use of different chemical and physical agents is still the most common 12 approach for killing cancer cells. The mechanism of action of chemotherapy drugs 13 will directly kill cancer cells or stop their proliferation by inducing a cellular 14 response linked to the mechanism of action of the drug. Substances such as TPL 15 and THZ1 that directly impact the activities of TFIIH have a high potential for use in 16
cancer treatment. In this study, we performed a systematic analysis of the effects 17 and response to these drugs, primarily TPL, in the MCF10A-ErSrc oncogenesis 18 model. Our results strongly suggest that TF tumour cells exhibited increased 19 sensitivity to TPL or THZ1 as compared to their NTF counterparts and that the 20 combination of both drugs had an additive effect on cell death. From a mechanistic 21 point of view, we found that even though TPL and THZ1 directly affect transcription 22 initiation by RNAPII of the majority of genes, specific genes are overexpressed as 23 a result of the transcriptional stress to which the cells are submitted upon treatment 24 with these drugs, underscoring the possibility to target these genes in conjunction 25
with TFIIH inhibitors to kill cancer cells. 26
In this oncogenic model, both TPL and THZ1 were found to kill cells via 27 apoptosis, stop proliferation one replication cycle earlier in TF cells than in NTF 28 cells and arrest cells in G 1 . As expected, co-treatment with TPL and THZ1 had an 29 additive effect on cell viability. Interestingly, the combination of TPL and THZ1 30 killed preferentially the transformed (cancerous) cells with high efficacy. These 31 results also suggest that the simultaneous use of substances that affect different 1 TFIIH functions is an interesting alternative to treat cancer and opens the 2 possibility of searching for new drugs that may affect other TFIIH subunits, 3 particularly if we consider the hepatotoxic effect of TPL and its derivatives (65). 4
Inhibition of transcription by TPL induces the proteasome-dependent 5 degradation of RNAPII (66,67). It has been proposed that TPL induces the 6 degradation of the polymerase following phosphorylation of POLR2A, the largest 7 subunit of RNAPII by CDK7 (66). We report here that incubation with TPL induced 8 the degradation not only of RNAPII but also of XPB as well as of P52 and P8, but it 9 did not affect other TFIIH subunits. THZ1, which inhibits the kinase activity of 10 CDK7, did not have any effect on the RNAPII and TFIIH protein levels. 11
It is known that the interaction of XPB with P52 and P8 modulates its 12
ATPase activity (43,45,68), and the recently solved structure of the TFIIH core 13
shows that the N-terminal domain of XPB and the clutch domain of P52 have a 14 similar fold and form a symmetric dimer. This interaction is not close to the ATPase 15
domain, suggesting that regulation of ATPase activity occurs through the combined 16
interaction of P52 and P8 with XPB (38). Accordingly, our findings show that the 17 covalent binding of TPL to the ATPase domain of XPB destabilizes its interaction 18 with P52, hindering the assembly of the subunits Furthermore, our computational 19 study allowed us to propose that the dissociation/degradation of the XPB-P52-P8 20 submodule is mainly caused by the separation of XPB HD1-HD2 induced by the 21 presence of TPL at the domain interface. Additionally, these results suggest that in 22 the context of TFIIH, XPB, P52 and P8 form a submodule that is stable only when 23 the three subunits are interacting and that the other TFIIH modules are not affected 24 in its absence. This idea is consistent with the conformation and organization 25 model described in the recently solved structure of the TFIIH core (38). 26
Intriguingly, degradation of RNAPII, as well as the XPB-P52-P8 submodule 27 was accelerated in TF cells incubated with TPL. Thus, it is feasible the mechanism 28 that increases the sensitivity of TF cells to TPL is partially due to the high 29 proliferation rate of these cells, the turnover of these proteins is not fast enough to 30 compensate for RNAPII depletion and, as a consequence, the effect on global 1 transcription is enhanced. 2 Several reports on the effect of TPL using PRO-Seq and GRO-Seq have 3
shown that the immediate effect is the reduction in transcription initiation of at least 4 90% of genes (21, 22) . These studies were performed after short incubation times, 5 with extremely high concentrations (10-500 µM) of TPL, but when the levels of 6 RNAPII were not affected. We analysed the transcriptome of NTF and TF cells 7 under conditions in which the levels of RNAPII were reduced by half, without 8 affecting cell viability, however we detected that many transcripts were 9 downregulated and many were upregulated. These results correlate with our data 10 in Drosophila, in which both up-and downregulated transcripts were observed in 11 P8 and P52 mutant organisms (47,48). Interestingly, the increase in the levels of 12 several specific genes in response to TPL also occurred in other breast cancer cell 13 lines. In similarity with our results, it has been documented that UV irradiation 14 causes the degradation of the RNAPII, but with the remaining RNAPII, the cell 15 overexpress specific genes as response to this insult. A similar situation may be 16
operating as a response to TPL (69). Furthermore, our ChIP-Seq results showed 17 that the increase in the RNA levels of many genes was correlated with an increase 18 in the occupancy of RNAPII on the corresponding promoters as well as in the gene 19 bodies and qRT-PCR of intronic sequences confirmed that it is due to an 20 enhancement of transcription. This is supported by the fact that the corresponding 21 protein products of the genes analysed here also increase after the TPL treatment. 22
An explanation for this phenomenon could be that, as recently reported (70), TPL 23 inhibits transcription by its interaction with XPB, but if XPB is not present, then 24 transcription is not inhibited. In support of this hypothesis, we found that TPL 25 induced degradation of the XPB-P52-P8 submodule. Although it is feasible that 26 under our experimental conditions, some genes were not affected by TPL, 27
probably because some genes do not require XPB as it has been shown in yeast 28 (15), this hypothesis is not supported by the observation that the response is the 29 overexpression of specific genes, with a significant increase in the corresponding 30 RNA levels and protein products. In addition, we observed that numerous genes 31 upregulated by TPL were also upregulated in cells treated with THZ1, which 1 inhibits CDK7 but does not affect the levels of the TFIIH subunits or RNAPII. 2 Therefore, our data evidence that TPL and THZ1 activate a mechanism of gene 3 response to transcriptional stress in treated cells. 4 TPL is a very effective substance for killing cancer cells, and related 5 compounds are now in clinical phases of development. However, one of the 6 problems with the use of TPL in patients is that it is highly toxic, and off-target 7 effects cannot be ignored (20, 65) . Therefore, finding new targets to enhance the 8 effect of reduced concentrations of TPL is very attractive. Here, we analysed only 9 five of many other possible targets found to be overexpressed in response to TPL 10 and in four, its depletion enhances the toxic effect of TPL at low concentrations. 11
These results suggest that many of the other gene products overexpressed in 12 response to TPL may improve the anti-tumoural capacity of TPL, opening a new 13 avenue to complement the attack on the transcriptional addiction of cancer cells. 14
Although treatment with TPL at high doses eventually killed most TF cells, 15
the circumstances may be different under in vivo conditions, and it is possible that 16 many of the cancerous cells in the tumour are exposed to lower concentrations of 17 TPL, allowing them to respond to transcriptional stress, by upregulating the 18 transcription level of some of the genes we report. This gene response is relevant 19
for the treatment of tumours by TPL or THZ1, more so considering that some 20 genes that we found to be over-activated encode factors that promote 21 tumourigenesis and/or metastasis. 22
In conclusion, the results presented here show that cells have the capacity 23 to respond to the transcriptional insult caused by TPL by overexpressing some 24 genes. Some of these genes are also overexpressed in response to THZ1, and 25 these genes are possible targets in combination with TPL to preferentially kill 26 cancer cells. However, this study also invokes several questions. For instance, 27 does the depletion of genes overexpressed in response to transcriptional stress 28 also enhance the effect of THZ1 on cancer cells? What is the mechanism that 29 potentiates the effect of TPL by depleting genes that have different functions, such 30 as ID2, HEXIM1 and CRY2? Is the overexpression of some genes by TPL is 31 achieved via only one specific response pathway, or are many pathways involved? 1
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37
non-transformed + triptolide (NTF, green), transformed (TF, red) and transformed + triptolide 1 displacement suffered by the cells when are treated with TPL towards the TSS-5'. Note the 2 presence of two RNAPII picks, without TPL the major pick corresponds to paused RNAPII and with 3 TPL the major pick corresponds to initiating RNAPII. Also note that after TPL treatment in some 4 promoters RNAPII is maintained paused.
(B)
Relation of the occupancy of the RNAPII in gene promoters after the TPL treatment in NTF,
6
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